EMA recommends 4SC's resminostat for orphan designation
This article was originally published in Scrip
The European Medicines Agency (EMA) has adopted a positive opinion for 4SC's resminostat to be given orphan drug designation for the treatment of hepatocellular carcinoma, which was a second piece of recent good news for the company, as they were able to present positive data for the drug in June (scripintelligence.com, scripintelligence.com, 23 June 2011). 4SC now has lots riding on resminostat's success, as its share price plunged by a third last month when its lead candidate, vidofludimus, failed to meet its primary endpoint (scripintelligence.com scripintelligence.com, 8 June 2011).
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.